Eli Lilly and Co (LLY) : Budros Ruhlin Roe reduced its stake in Eli Lilly and Co by 3.62% during the most recent quarter end. The investment management company now holds a total of 26,139 shares of Eli Lilly and Co which is valued at $2,096,871 after selling 982 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Eli Lilly and Co makes up approximately 0.69% of Budros Ruhlin Roe’s portfolio.
Other Hedge Funds, Including , Dorsey Whitney Trust Co boosted its stake in LLY in the latest quarter, The investment management firm added 1,460 additional shares and now holds a total of 21,749 shares of Eli Lilly and Co which is valued at $1,744,705. Eli Lilly and Co makes up approx 0.39% of Dorsey Whitney Trust Co’s portfolio.Gabelli Funds reduced its stake in LLY by selling 32,000 shares or 5.5% in the most recent quarter. The Hedge Fund company now holds 550,000 shares of LLY which is valued at $44,858,000. Eli Lilly and Co makes up approx 0.27% of Gabelli Funds’s portfolio.Oak Ridge Investments reduced its stake in LLY by selling 276,232 shares or 52.12% in the most recent quarter. The Hedge Fund company now holds 253,718 shares of LLY which is valued at $20,693,240. Eli Lilly and Co makes up approx 0.50% of Oak Ridge Investments’s portfolio. Genesee Valley Trust Co added LLY to its portfolio by purchasing 2,688 company shares during the most recent quarter which is valued at $224,179. Eli Lilly and Co makes up approx 0.15% of Genesee Valley Trust Co’s portfolio.Eqis Capital Management boosted its stake in LLY in the latest quarter, The investment management firm added 181 additional shares and now holds a total of 10,082 shares of Eli Lilly and Co which is valued at $806,056. Eli Lilly and Co makes up approx 0.05% of Eqis Capital Management’s portfolio.
Eli Lilly and Co closed down -0.72 points or -0.90% at $79.06 with 37,46,012 shares getting traded on Friday. Post opening the session at $79.55, the shares hit an intraday low of $78.78 and an intraday high of $79.79 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.